52 related articles for article (PubMed ID: 36351652)
1. A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility.
Chen SJ; Hashimoto K; Fujio K; Hayashi K; Paul SK; Yuzuriha A; Qiu WY; Nakamura E; Kanashiro MA; Kabata M; Nakamura S; Sugimoto N; Kaneda A; Yamamoto T; Saito H; Takayama N; Eto K
Nat Commun; 2024 Mar; 15(1):2588. PubMed ID: 38519457
[TBL] [Abstract][Full Text] [Related]
2. Advances in Human Leukocyte Antigen Testing Technologies and Management Strategies for Platelet Transfusion Refractoriness.
Sullivan HC; Borge PD; Gammon RR; Gandhi M; Philogene MC; Wu Y; Kopko PM
Arch Pathol Lab Med; 2024 Jun; ():. PubMed ID: 38871350
[TBL] [Abstract][Full Text] [Related]
3. Commentary: An enzymatic pathway in the human gut microbiome that converts A to universal O type blood.
Owoicho O; Olwal CO; Quaye O
Front Immunol; 2020; 11():772. PubMed ID: 32411149
[No Abstract] [Full Text] [Related]
4. Ex Vivo Production of Platelets From iPSCs: The iPLAT1 Study and Beyond.
Sugimoto N; Eto K
Hemasphere; 2023 Jun; 7(6):e884. PubMed ID: 37213327
[No Abstract] [Full Text] [Related]
5. Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.
He R; Weng Z; Liu Y; Li B; Wang W; Meng W; Li B; Li L
Stem Cell Rev Rep; 2023 Nov; 19(8):2557-2575. PubMed ID: 37755647
[TBL] [Abstract][Full Text] [Related]
6. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.
Sugimoto N; Nakamura S; Shimizu S; Shigemasa A; Kanda J; Matsuyama N; Tanaka M; Hayashi T; Fuchizaki A; Nogawa M; Watanabe N; Okamoto S; Handa M; Sawaguchi A; Momose D; Koh KR; Tani Y; Takaori-Kondo A; Eto K
Blood Adv; 2022 Dec; 6(23):6056-6069. PubMed ID: 36149941
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.
Chen SJ; Sugimoto N; Eto K
Int J Hematol; 2023 Mar; 117(3):349-355. PubMed ID: 36574167
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo generation of platelet products from human iPS cells.
Nakamura S; Sugimoto N; Eto K
Inflamm Regen; 2020 Dec; 40(1):30. PubMed ID: 33292717
[TBL] [Abstract][Full Text] [Related]
9. Platelet production from induced pluripotent stem cells.
Sugimoto N; Eto K
J Thromb Haemost; 2017 Sep; 15(9):1717-1727. PubMed ID: 28752663
[TBL] [Abstract][Full Text] [Related]
10. Mass production of iPSC-derived platelets toward the clinical application.
Kayama A; Eto K
Regen Ther; 2024 Mar; 25():213-219. PubMed ID: 38260088
[TBL] [Abstract][Full Text] [Related]
11. [Clinical applications of iPS cell-derived platelets].
Sugimoto N; Eto K
Rinsho Ketsueki; 2022; 63(10):1430-1439. PubMed ID: 36351652
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
